

Transcranial magnetic stimulation in the treatment of bipolar depression

| | | |
|--|---|---|
| Submission date 04/06/2021 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 27/05/2022 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 04/06/2024 | Condition category Mental and Behavioural Disorders | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Bipolar disorder (BD) is a severe mental disorder with a recurrent course. Manic episodes are a prominent feature of BD, but the burden of major depression episodes (bipolar depression [BDE]) is even more substantial. However, treatment of BDE is still limited, and only a few medications have shown definite effectiveness. Repetitive transcranial magnetic stimulation (rTMS) belongs to non-invasive brain stimulation (NIBS) methods and is approved to treat major depression, but its importance to BDE is not yet fully understood. This study aims to evaluate the effectiveness and safety of rTMS in treating patients with bipolar depression. The study lasts 4 weeks and is designed as randomized with three different rTMS procedures, including placebo stimulation.

Who can participate?

Patients with bipolar disorder aged between 18 to 70 years who are currently in depression and existing treatment does not help them sufficiently.

What does the study involve?

The study involves 20 rTMS sessions (one session every weekday) during the 4 weeks. Participants are randomly allocated to one of three different rTMS interventions: two of them are real rTMS, and one is placebo stimulation. Depression severity and its change are assessed weekly using objective and self-assessed scales. In addition, for safety reasons and the rTMS coil targeting, electroencephalogram (EEG) and magnetic resonance imaging (MRI) examinations are scheduled before and at the end of the study.

What are the possible benefits and risks of participating?

Participating could benefit the alleviation of depressive symptoms. The risk of participation includes side effects such as headache, facial muscles twitching, hearing difficulties, or mood change/swinging, which are mild and transient in most cases.

Where is the study run from?

National Institute of Mental Health, Klecany (Czech Republic)

When is the study starting and how long is it expected to run for? (what are the overall start and end dates?)

May 2015 to January 2021

Who is funding the study?

Czech Health Research Council (Czech Republic)

Who is the main contact?

Dr Tomas Novak

tomas.novak@nudz.cz

Contact information

Type(s)

Public

Contact name

Dr Tomas Novak

ORCID ID

<http://orcid.org/0000-0001-9156-9654>

Contact details

Topolova 748

Klecany

Czech Republic

25067

+420 (0)283088162

tomas.novak@nudz.cz

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

AZV no. 16-31380A

Study information

Scientific Title

High-frequency MRI-guided repetitive transcranial magnetic stimulation as an add-on treatment in bipolar I or II depression: a randomized, sham-controlled, double-blind, parallel study

Acronym

TRAMABID

Study objectives

The primary objective of the proposed project is to compare the efficacy and tolerability of high-frequency (HF) repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (LDL) and the right ventrolateral prefrontal cortex (RVL) with sham TMS in the treatment of bipolar depression.

The mean change in total scores on the Montgomery–Åsberg Depression Rating Scale (MADRS) from the baseline to week 4 is the primary outcome measure. The secondary efficacy measures are mean change in QIDS-SR (self-assessment) and CGI-BD scores over the study period, and the response and remission rates, as defined by a 50% or greater reduction in MADRS total scores and as a score of 10 or less in the MADRS total scores at the end of treatment. The dropout rates and adverse events rates are additional secondary outcome parameters.

H1: The reduction of depressive symptoms is higher in both active rTMS groups (LDL, RVL) compare to sham rTMS at the end of the 4-week study period.

H2: The number of responders is higher in both active rTMS groups compare to sham rTMS at the end of the 4-week study period.

H3: The number of subjects who dropped out from the acute phase of the study for any reason is not different across treatment groups.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 17/06/2015, Ethics Board (Commission) of National Institute of Mental Health (Topolova 748, 250 67 Klecany, Czech Republic; +420 (0)283088312; ek@nudz.cz), ref: 78/15

Study design

Four-week randomized sham-controlled double-blind three-group parallel study with 4-week open-label follow-up

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

See trial outputs table

Health condition(s) or problem(s) studied

Bipolar I or II disorder, current episode depressive, moderate to severe, without psychotic symptoms

Interventions

Patients are randomly allocated according to permuted block design with a fixed block size of 6 to one of the three intervention groups:

1. Active 10 Hz rTMS applied to the left dorsolateral prefrontal cortex (DLPFC) (BA 46), 100% of motor threshold, 2 s on, 8 s off, 10 minutes duration; 1200 pulses per session; 20 sessions
2. Active 10 Hz rTMS applied to the right ventrolateral prefrontal cortex (VLPFC) (BA 47), 100% of motor threshold, 2 s on, 8 s off, 10 minutes duration; 1200 pulses per session; 20 sessions
3. Sham rTMS with a sham coil applied either to left DLPFC or to right VLPFC (randomly per ten subjects); 20 sessions

Intervention Type

Device

Phase

Phase III/IV

Drug/device/biological/vaccine name(s)

MagPro R30 stimulator (MagVenture, Denmark) and Cool-B65 A/P coil

Primary outcome measure

Depression severity is measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) from baseline to week 4

Secondary outcome measures

1. Depression severity is measured using the Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) and overall psychopathology related to bipolar disorder is measured using the Clinical Global Impression-Bipolar (CGI-BP) scores from baseline to week 4
2. Response and remission rates, as defined by a 50% or greater reduction in MADRS total scores and as a score of 10 or less in the MADRS total scores at the end of treatment
3. Dropout rates and adverse events rates measured using the Adverse Effects Questionnaire at weeks 1, 2, 3, and 4

Overall study start date

01/05/2015

Completion date

30/01/2021

Eligibility

Key inclusion criteria

1. Both inpatients and outpatients with bipolar disorder I and II, currently in the major depressive episode (BDE) diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria
2. Females or males
3. Age 18 to 70 years
4. Moderate to severe depression based on the Montgomery–Åsberg Depression Rating Scale (MADRS) score ≥ 20
5. Current BDE lasting at least 4 weeks but no more than 12 months
6. Taking mood stabilizers (lithium, valproate, lamotrigine) or second-generation antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone) at a steady dosage for at least 4 weeks before

screening and it is clinically appropriate to continue during the trial period
7. Failed to respond to at least one adequate antidepressant trial in the current BDE
8. Being able and willing to provide written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

60 (20 per group)

Total final enrolment

60

Key exclusion criteria

1. Psychotic symptoms during the current BDE
2. Hypomanic, manic, or mixed features at screening or at the baseline visit (the Young Mania Rating Scale (YMRS) >11)
3. Significant risk of suicidal behavior based upon MINI or MADRS item 10 (suicidal thoughts) ≥ 4 at screening or baseline visit
4. Eight or more episodes of BD within 12 months prior to study enrollment
5. History of any DSM-IV Axis I diagnosis other than bipolar disorder I and II, with exception of anxiety disorders
6. History of substance use disorders (except nicotine addiction) in the last year
7. Personality disorder that makes participation in the trial difficult in the opinion of the investigator
8. Pregnancy or breastfeeding
9. Contraindication for rTMS therapy or MRI scanning (history of epilepsy or any medical condition likely to increase risk of seizure, mass brain lesions, cerebrovascular accident, a history of major head trauma with unconsciousness, metal implants or fragments in the head, pacemaker, or other electronic devices)
10. Electroconvulsive therapy within the last 6 months

Date of first enrolment

01/01/2017

Date of final enrolment

30/11/2020

Locations**Countries of recruitment**

Czech Republic

Study participating centre
National Institute of Mental Health
Topolova 748
Klecany
Czech Republic
25067

Sponsor information

Organisation
National Institute of Mental Health

Sponsor details
Topolova 748
Klecany
Czech Republic
25067
+420 (0)283 088 410
sr@nudz.cz

Sponsor type
Research organisation

Website
<https://www.nudz.cz/en/>

ROR
<https://ror.org/05xj56w78>

Funder(s)

Funder type
Research council

Funder Name
Agentura Pro Zdravotnický Výzkum České Republiky

Alternative Name(s)
Czech Health Research Council, AZV ČR

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Czech Republic

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal

Intention to publish date

01/06/2023

Individual participant data (IPD) sharing plan

Data of primary and secondary measurements will be shared upon reasonable request (additional analyses, meta-analyses). Data will be provided as fully anonymized. Contact for access to the dataset: Tomas Novak (tomas.novak@nudz.cz).

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---------|--------------|------------|----------------|-----------------|
| Participant information sheet | | | 05/05/2022 | No | Yes |
| Protocol file | | | 05/05/2022 | No | No |
| Results article | | 25/05/2024 | 04/06/2024 | Yes | No |